Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BECTON DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Becton, Dickinson and Company to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2020 | 09:43am EDT

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Becton, Dickinson and Company (“Becton” or the “Company”) (NYSE:BDX) of the April 27, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Becton stock or options between November 5, 2019 and February 5, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/BDX. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Becton securities between November 5, 2019 and February 5, 2020 (the “Class Period”). The case, Kabak v. Becton Dickinson & Company, No. 20-cv-02155 was filed on February 27, 2020 and has been assigned to Judge Stanley R. Chesler.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose: (1) that certain of Becton’s Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) that, as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to “make enhancements;” (3) that the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) that, as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Specifically, on February 6, 2020, Becton lowered its fiscal 2020 guidance, announcing that it expected revenue to increase by only 1.5 to 2.5 percent, “to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.” According to the Company, the software remediation plan for the Alaris system “will require additional regulatory filings,” and existing customers would have “access to the Alaris System under medical necessity.”

Moreover, Becton disclosed that it had recalled certain of its Alaris systems and that it would only sell the infusion pump to existing customers who demonstrate a medical necessity.

On this news, Becton’s stock price fell from $285.99 per share on February 5, 2020 to a closing price of $252.25 per share on February 6, 2020—a $33.74 or 11.80% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Becton’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BECTON, DICKINSON AND COMP
05/26BECTON DICKINSON & CO : Material Modification to Rights of Security Holders, Ame..
AQ
05/26BECTON DICKINSON AND : BD to Present at Jefferies Virtual Healthcare Conference
PR
05/21BECTON DICKINSON AND : BD Prices Offerings of $1.5 Billion of Common Stock and $..
PR
05/20BECTON DICKINSON & CO : Creation of a Direct Financial Obligation or an Obligati..
AQ
05/20BECTON DICKINSON AND : Q2 2020 Earnings Presentation
PU
05/19BECTON DICKINSON AND : BD Announces Offerings of $1.5 billion of Common Stock an..
PR
05/13BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-..
AQ
05/07BECTON DICKINSON AND : & CO Management's Discussion and Analysis of Financial Co..
AQ
05/07BECTON DICKINSON : Fiscal 2Q Earnings Snapshot
AQ
05/07BECTON DICKINSON & CO : Results of Operations and Financial Condition, Financial..
AQ
More news
Financials (USD)
Sales 2020 16 922 M
EBIT 2020 4 119 M
Net income 2020 1 250 M
Debt 2020 16 080 M
Yield 2020 1,45%
P/E ratio 2020 49,2x
P/E ratio 2021 23,8x
EV / Sales2020 5,05x
EV / Sales2021 4,57x
Capitalization 69 457 M
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMP
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 273,94 $
Last Close Price 234,80 $
Spread / Highest target 27,8%
Spread / Average Target 16,7%
Spread / Lowest Target 4,34%
EPS Revisions
Managers
NameTitle
Thomas E. Polen President, Chief Executive Officer & Director
Vincent A. Forlenza Executive Chairman
Christopher R. Reidy Chief Financial Officer, CAO & EVP-Administration
John A. DeFord Chief Technology Officer & Executive VP
William R. Sigmund Chief Medical Officer & EVP
Sector and Competitors